These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27055559)

  • 1. Dose-escalation study for the targeting of CD44v
    Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
    Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
    Shitara K; Doi T; Nagano O; Fukutani M; Hasegawa H; Nomura S; Sato A; Kuwata T; Asai K; Einaga Y; Tsuchihashi K; Suina K; Maeda Y; Saya H; Ohtsu A
    Gastric Cancer; 2017 Nov; 20(6):1004-1009. PubMed ID: 28466360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Redox regulation in cancer stem cells].
    Saya H
    Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
    Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
    Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
    Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
    Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
    J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
    Nagano O; Okazaki S; Saya H
    Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
    Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
    Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
    Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
    Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
    Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
    Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
    Wang F; Yang Y
    Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
    Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
    Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epithelial-mesenchymal transition with cancer stem cell-like marker as predictors of recurrence after radical resection for gastric cancer.
    Xu GF; Zhang WJ; Sun Q; Xu X; Zou X; Guan W
    World J Surg Oncol; 2014 Dec; 12():368. PubMed ID: 25441488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
    Wada T; Ishimoto T; Seishima R; Tsuchihashi K; Yoshikawa M; Oshima H; Oshima M; Masuko T; Wright NA; Furuhashi S; Hirashima K; Baba H; Kitagawa Y; Saya H; Nagano O
    Cancer Sci; 2013 Oct; 104(10):1323-9. PubMed ID: 23848514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical research of targeting therapy for cancer stem cells].
    Shitara K; Doi T
    Nihon Rinsho; 2015 May; 73(5):823-30. PubMed ID: 25985638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
    Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
    J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.